Diadema Partners LP
Diadema Partners LP is a newly established investment adviser firm headquartered in Morristown, New Jersey. Founded in March 2024 as a Delaware limited partnership, it is primarily owned and led by Chief Investment Officer Timothy Beau Bassett. The firm provides investment advisory and portfolio management services primarily for pooled investment vehicles and institutional clients, managing assets for 7 clients with 5 financial advisors. Diadema serves businesses and investment vehicles and employs tailored portfolio management strategies focused on long-term growth and personalized client objectives.
Investment Strategy
Diadema Partners LP employs custom portfolio management strategies for institutional clients, pooled investment vehicles, and businesses aimed at long-term capital appreciation. The firm is focused on actively managing diversified portfolios, with significant allocations to healthcare and biotech equities, as shown by top positions in companies like Vertex Pharmaceuticals, Amgen, and Eli Lilly. The advisory team uses a combination of fundamental and quantitative research to identify opportunities within select sectors and employs both long and short equity strategies. Compensation structures may include fees based on assets under management and performance relative to a benchmark, allowing for better alignment with client financial objectives.
Top Holdings
Equity Positions (45)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
S SLNO | SOLENO THERAPEUTICS INC | 7.25% | $23.8M | 284,152 | $73.03 | $83.78 | +$17.2M |
A AMGN | AMGEN INC | 4.43% | $14.5M | 52,100 | $279.21 | $279.21 | +$14.5M |
T TGTX | TG THERAPEUTICS INC | 4.07% | $13.4M | 371,448 | $36.71 | $35.99 | +$5.2M |
N NBIX | NEUROCRINE BIOSCIENCES INC | 3.60% | $11.8M | 94,042 | $115.70 | $125.69 | +$4.9M |
L LLY | ELI LILLY & CO | 3.52% | $11.5M | 14,816 | $825.91 | $779.53 | -$4.4M |
Options Positions (10)
| Ticker | Security | Action | Type | Notional Value | Contracts | Underlying Price | Premium Paid | Change (Contracts) | Change (Value) |
|---|---|---|---|---|---|---|---|---|---|
A AMGN | AMGEN INC | Bought | Put | $17.3M | 621 | $279.21 | $306.34 | +100 | +$1.1M |
L LLY | ELI LILLY & CO | — | Put | $16.1M | 207 | $779.53 | $825.91 | 0 | -$960.1K |
X XBI | SPDR SERIES TRUST | New | Call | $8.3M | 1,000 | $82.93 | $82.93 | +1,000 | +$8.3M |
R RARE | ULTRAGENYX PHARMACEUTICAL IN | Bought | Call | $7.9M | 2,170 | $36.36 | $37.69 | +1,000 | +$3.7M |
L LLY | ELI LILLY & CO | — | Call | $7.8M | 100 | $779.53 | $825.91 | 0 | -$463.8K |